Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Aumolertinib
2. Hs-10296
3. N-(5-((4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethyl-methylamino)-4-methoxyphenyl)prop-2-enamide
1. Hs-10296
2. 1899921-05-1
3. Aumolertinib
4. Ameile
5. Aumolertinib [usan]
6. Hs-10297
7. Egfr T790m Inhibitor Hs-10296
8. Chembl4761468
9. T4rs462g19
10. N-(5-((4-(1-cyclopropyl-1h-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
11. 2-propenamide, N-(5-((4-(1-cyclopropyl-1h-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-
12. N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
13. Aumolertinib [inn]
14. Almonertinib [who-dd]
15. Unii-t4rs462g19
16. Schembl17683063
17. Gtpl11136
18. Eq143
19. Ex-a3721
20. Zad92105
21. Hs 10296 [who-dd]
22. Bdbm50557548
23. Eq-143
24. S8817
25. Who 11295
26. At30756
27. Hs10296
28. As-84436
29. Example 26 [wo2016054987a1]
30. Hs-10206
31. Hy-112823
32. Cs-0066162
| Molecular Weight | 525.6 g/mol |
|---|---|
| Molecular Formula | C30H35N7O2 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 11 |
| Exact Mass | 525.28522338 g/mol |
| Monoisotopic Mass | 525.28522338 g/mol |
| Topological Polar Surface Area | 87.6 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 823 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Almonertinib inhibits EGFR tyrosine kinase targeting EGFR-sensitizing and T790M resistance mutations.
Drugs in Development
Details:
(SHR-A2009) is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): SHR-A2009,Aumolertinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 19, 2025
Lead Product(s) : SHR-A2009,Aumolertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : (SHR-A2009) is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 19, 2025
Details:
Aumolertinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Aumolertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 19, 2025
Lead Product(s) : Aumolertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Aumolertinib in European Participants with Non-Small Cell Lung Cancer
Details : Aumolertinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2025
Details:
Aumolertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Aumolertinib,Midazolam
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 13, 2025
Lead Product(s) : Aumolertinib,Midazolam
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aumolertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 13, 2025
Details:
HS-20117 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): HS-20117,Aumolertinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 16, 2024
Lead Product(s) : HS-20117,Aumolertinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HS-20117 is a Other Large Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 16, 2024
Details:
HS-10241 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): HS-10241,Aumolertinib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 01, 2023
Lead Product(s) : HS-10241,Aumolertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HS-10241 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 01, 2023
Details:
Almonertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Aumolertinib,SHR-1701
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 17, 2022
Lead Product(s) : Aumolertinib,SHR-1701
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Almonertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 17, 2022
Details:
Aumolertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Aumolertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 09, 2022
Lead Product(s) : Aumolertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aumolertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2022
Details:
Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.
Lead Product(s): Aumolertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2022
Lead Product(s) : Aumolertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting
Details : Aumolertinib is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR- sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2022
Details:
Aumolertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Lead Product(s): Aumolertinib,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 20, 2022
Lead Product(s) : Aumolertinib,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143
Details : Aumolertinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Liver Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 20, 2022
Details:
Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
Lead Product(s): Aumolertinib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Abdul Latif Jameel Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 22, 2021
Lead Product(s) : Aumolertinib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Abdul Latif Jameel Health
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Through the agreement, Abdul Latif Jameel Health will become EQRx’s regulatory and commercial partner for aumolertinib and sugemalimab, if approved, in selected markets throughout the Middle East region, as well as in Turkey and all of Africa.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
54
PharmaCompass offers a list of Aumolertinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Aumolertinib manufacturer or Aumolertinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Aumolertinib manufacturer or Aumolertinib supplier.
PharmaCompass also assists you with knowing the Aumolertinib API Price utilized in the formulation of products. Aumolertinib API Price is not always fixed or binding as the Aumolertinib Price is obtained through a variety of data sources. The Aumolertinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Aumolertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aumolertinib, including repackagers and relabelers. The FDA regulates Aumolertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aumolertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Aumolertinib supplier is an individual or a company that provides Aumolertinib active pharmaceutical ingredient (API) or Aumolertinib finished formulations upon request. The Aumolertinib suppliers may include Aumolertinib API manufacturers, exporters, distributors and traders.
Aumolertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aumolertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aumolertinib GMP manufacturer or Aumolertinib GMP API supplier for your needs.
A Aumolertinib CoA (Certificate of Analysis) is a formal document that attests to Aumolertinib's compliance with Aumolertinib specifications and serves as a tool for batch-level quality control.
Aumolertinib CoA mostly includes findings from lab analyses of a specific batch. For each Aumolertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aumolertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Aumolertinib EP), Aumolertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aumolertinib USP).
